Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Agrippal

- PMLiVE

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Latest BACE inhibitor to run into trouble

- PMLiVE

New efficacy data boosts Aimovig’s migraine market lead

Data should help boost uptake

Novartis day

Novartis close to US bribery settlement

Company faces huge damages pay out

- PMLiVE

Rival Novartis, Merck drugs square up on rare lung cancer at ASCO

An inflection point for MET-inhibitor class

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

Novartis day

FDA clears Novartis’ new breast cancer drug Piqray

Blockbuster potential for PI3K drug

- PMLiVE

Novartis sees five new $1bn-plus launches in next two years

CEO defends likely high price of Zolgensma

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

- PMLiVE

Novartis builds case for SMA gene therapy as FDA verdict looms

One shot therapy provided rapid improvement in motor function

Infographic: The vaccine opportunity in Asia

Asia is home to 60% of the world’s population and is one of the fastest growing vaccine markets in the world. A rising demand for better healthcare infrastructure and high...

Research Partnership

- PMLiVE

Deadly measles outbreaks on the rise, social media called to account

Firms called on to fight anti-vax fake news

- PMLiVE

Alcon spun off, leaner Novartis raises profit forecast

Expects three new launches in 2019

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links